Alnylam Pharmaceuticals
ALNY
#452
Rank
HK$402.51 B
Marketcap
HK$3,047
Share price
-1.52%
Change (1 day)
60.60%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of December 2025 (TTM): 16.4

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 225. At the end of 2025 the company had a P/S ratio of 18.2.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2025

PS ratio at the end of each year

Year P/S ratio Change
202518.233.52%
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Arrowhead Pharmaceuticals
ARWR
11.5-29.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
5.62-65.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.9594-94.14%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
1.69-89.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
4.58-72.03%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
2.44-85.11%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
2.07-87.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel